查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1992863

血漿衍生產品市場：2026-2032 年全球市場按產品類型、原料、分銷管道、應用和最終用戶進行預測。

Blood Plasma Derivatives Market by Product Type, Source, Distribution Channel, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，血漿衍生產品市場價值將達到 302.4 億美元，到 2026 年將成長至 321.5 億美元，到 2032 年將達到 478.5 億美元，複合年成長率為 6.77%。

主要市場統計數據
基準年 2025 302.4億美元
預計年份：2026年 321.5億美元
預測年份 2032 478.5億美元
複合年成長率 (%) 6.77%

這篇精闢而深刻的概述涵蓋了科學進步、供應鏈韌性以及正在重塑患者獲得血漿衍生和重組療法的醫療保健服務模式的演變。

血漿衍生療法和重組生物製藥的治療格局正進入一個以加速科學創新、監管重點轉變和整個供應鏈運作複雜性日益增加為特徵的新階段。重組技術的進步和生產控制的改進擴大了可用治療方案的範圍。同時，診斷準確性的提高和患者分層技術的進步最佳化了血友病、原發性免疫力缺乏缺陷病和某些神經系統疾病等疾病的臨床路徑。

對分子層級創新、加強監管和分銷數位化如何重新定義血漿衍生和重組療法的競爭格局進行了冷靜的分析。

當前時期正經歷著變革性的變化，這些變化正在重新定義血漿衍生和重組治療藥物的研發、生產和交付。分子工程和細胞株最佳化的突破性進展提高了重組凝血因子的特異性和穩定性，與血漿衍生免疫球蛋白和白蛋白的分離純化技術的改進相輔相成。伴隨這些科學進步，數位化正在整個生產和分銷網路中推進，從而在整個產品生命週期中實現更好的可追溯性和品質保證。

對美國關稅政策的變化如何引發各產業的供應鏈重組、採購趨勢轉變和策略製造決策進行分析評估。

美國有關關稅和貿易措施的政策發展正對全球血漿衍生和重組產品生態系統產生連鎖反應。關稅調整會影響分離和重組生產所需的原料、特殊耗材和設備的成本結構。這些變化會波及契約製造關係和籌資策略，迫使製造商重新評估其採購地點和合約條款，以維持獲利能力和可靠性。

一個全面的、以細分為主導的洞察框架，將採購來源、最終用戶、分銷管道、產品類型和臨床應用聯繫起來，揭示了有針對性的策略重點。

細分市場分析揭示了每種產品類別和給藥模式的不同商業性和臨床因素，從而詳細展現了創新和投資的集中觀點。根據供應來源，市場分為血漿衍生和重組兩大類，其中重組方法透過分析因子IX和因子VIII不同的臨床和生產特性進行深入探討。這些差異影響研發進度、監管路徑和臨床醫生的應用模式。根據最終用戶，評估區分了血友病治療中心、居家照護機構和醫院，每種機構對低溫運輸管理、病患教育和依從性計畫都有獨特的要求，這些要求影響著分銷和支援服務。

一項多方面的區域分析揭示了美洲、歐洲、中東和非洲以及亞太地區如何影響監管策略、製造地和患者獲取趨勢。

區域趨勢在塑造產業整體生產策略、監管互動和患者用藥途徑方面發揮著至關重要的作用。在美洲，成熟的製造群和密集的醫療網路支持血漿療法和重組療法的廣泛應用，同時成本效益和公平的用藥政策及報銷環境也在不斷發展完善。該地區的研究基礎設施和臨床試驗能力也為評估新治療方法和監測核准後安全性提供了重要平台。

從高階主管的觀點了成熟製造商、重組療法創新者和契約製造製造商如何透過夥伴關係、現代化和服務差異化來重建其競爭優勢。

競爭格局由眾多參與者構成：傳統血漿分餾生產商、重組蛋白工程創新者以及提供規模和技術專長的專業契約製造。主要企業正致力於透過整合血漿衍生產品和重組療法來實現產品組合多元化，以平衡供應風險並滿足多樣化的臨床需求。策略重點包括投資生產現代化、推廣病原體減少技術以及加強血漿捐贈者招募和留存計畫。

切實可行的建議著重於加強供應鏈韌性、加快數位化追溯以及調整商業化方法以滿足醫療服務提供者和支付方的期望。

該領域的領導企業應優先考慮能夠增強供應鏈韌性的整合策略，同時支援產品在臨床環境中的應用以及與支付方的合作。投資區域製造地和供應鏈冗餘將有助於降低貿易中斷和關稅相關成本壓力的風險，並能夠快速回應區域需求波動。同時，各企業應加速實施數位化品質系統和供應鏈可追溯性工具，以加強產品安全監控和合規性，進而提升臨床醫師和支付方的信心。

採用透明的混合方法研究途徑，結合專家訪談、監管審查和基於情境的分析，以檢驗策略見解並確保方法的嚴謹性。

本分析所依據的研究採用了一種混合方法，將與關鍵相關人員的對話與嚴謹的第二手資料檢驗相結合，以建立一個強大而令人信服的證據基礎。質性研究包括與臨床專家、生產負責人、監管專家和分銷合作夥伴進行結構化訪談和諮詢。這些訪談旨在了解不同治療領域的實際運作情況、應用促進因素以及感知到的障礙。研究還將這些觀點與技術文獻、監管指導文件和公開的臨床試驗註冊資訊進行交叉比對，以確保其與當前的科學和政策背景保持一致。

一項果斷的整合，強調透過協調科學創新、營運韌性和個人化商業化來改善病患就醫途徑的協調策略應對措施。

總之，血漿衍生療法和重組療法領域既蘊含機會也面臨挑戰，需要採取協調一致的策略應對措施。重組工程技術的進步和血漿分餾技術的改進正在拓展治療選擇，而隨著監管機構和支付方期望的提高，安全性、可追溯性和可驗證的真實世界療效變得日益重要。供應鏈的脆弱性和地緣政治貿易因素進一步增加了產業計畫的複雜性，凸顯了採購多元化和投資區域生產能力的重要性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 血漿衍生產品市場：依產品類型分類

  • 白蛋白
  • 凝血因子
    • 因子九
    • 因子 VIII
    • 纖維蛋白膠
  • 免疫球蛋白
    • 高免疫
    • 靜脈
    • 皮下

第9章：血漿衍生產品市場：依來源分類

  • 血漿衍生的
  • 重組
    • 因子九
    • 因子 VIII

第10章 血漿衍生產品市場：依分銷管道分類

  • 線上
  • 離線

第11章 血漿衍生市場：依應用領域分類

  • 血友病治療
  • 神經系統疾病
  • 原發性免疫力缺乏

第12章 血漿衍生產品市場：依最終用戶分類

  • 血友病治療中心
  • 居家照護
  • 醫院

第13章 血漿衍生市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 血漿衍生產品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 血漿衍生產品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國血漿衍生

第17章 中國血漿衍生市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory Limited（BPL）
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Behring GmbH
  • Emergent BioSolutions Inc.
  • Grifols, SA
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kamada Ltd.
  • Kedrion SpA
  • LFB SA
  • Octapharma AG
  • Reliance Life Sciences Pvt. Ltd.
  • Sanquin Plasma Products BV
  • Shanghai RAAS Blood Products Co., Ltd.
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • SK Plasma Co., Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: MRR-1A1A064C008F

The Blood Plasma Derivatives Market was valued at USD 30.24 billion in 2025 and is projected to grow to USD 32.15 billion in 2026, with a CAGR of 6.77%, reaching USD 47.85 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 30.24 billion
Estimated Year [2026] USD 32.15 billion
Forecast Year [2032] USD 47.85 billion
CAGR (%) 6.77%

An incisive overview framing scientific progress, supply chain resilience, and evolving care delivery models that are reshaping patient access to plasma-derived and recombinant therapeutics

The therapeutic landscape for blood plasma derivatives and recombinant biologics has entered a phase characterized by intensified scientific innovation, shifting regulatory priorities, and heightened operational complexity across supply chains. Advances in recombinant technologies and improved manufacturing controls have expanded the portfolio of available therapeutic options, while concurrent growth in diagnostic precision and patient stratification has refined clinical pathways for conditions such as hemophilia, primary immunodeficiency, and selected neurological disorders.

Alongside scientific progress, stakeholders face evolving expectations for product safety, traceability, and access. Manufacturers and providers must balance the imperative for rigorous donor screening and pathogen-reduction processes with the need to maintain continuity of supply. Health systems and treatment centers are increasingly integrating home-based care models and specialist clinic frameworks, prompting re-evaluation of distribution pathways and patient support mechanisms. Taken together, these dynamics set the stage for strategic decision-making by biopharmaceutical companies, clinicians, and payers who must adapt to an environment where therapeutic choice, supply resilience, and regulatory compliance converge.

A clear-eyed examination of how molecular innovations, regulatory tightening, and distribution digitalization are redefining competitive dynamics across plasma and recombinant therapeutics

The current period is marked by transformative shifts that are redefining how plasma-derived and recombinant therapies are developed, manufactured, and delivered. Breakthroughs in molecular engineering and cell-line optimization have increased the specificity and stability of recombinant coagulation factors, complementing improvements in fractionation and purification techniques for plasma-derived immunoglobulins and albumin. These scientific advances are paralleled by digitalization across manufacturing and distribution networks, enabling better traceability and quality assurance throughout the product lifecycle.

Regulatory authorities are placing greater emphasis on robust risk-mitigation strategies, including enhanced pathogen-detection protocols and lifecycle surveillance for novel biologics. At the same time, payers and health systems are prioritizing treatment modalities that demonstrate both clinical efficacy and operational efficiencies, driving adoption in home care settings and specialist clinics where appropriate. Market entrants and incumbents alike are forming strategic alliances to de-risk supply chains, scale capacity, and accelerate access to recombinant alternatives, thereby shifting competitive dynamics and incentivizing investments in vertical integration and regional manufacturing hubs. As a result, stakeholders must now navigate a landscape where scientific innovation, regulatory rigor, and commercial agility intersect to determine long-term positioning.

An analytical assessment of how changing United States tariff policies create supply chain realignments, procurement shifts, and strategic manufacturing decisions across the industry

Policy movements in the United States concerning tariffs and trade measures have had a cascading set of effects on the global ecosystem for plasma-derived and recombinant products. Tariff adjustments influence cost structures for raw materials, specialized consumables, and equipment needed for fractionation and recombinant production. These changes reverberate across contract manufacturing relationships and procurement strategies, prompting manufacturers to reassess sourcing footprints and contractual terms to preserve margin and reliability.

Beyond direct cost implications, tariff shifts can alter the geographic logic of supply chains, encouraging investments in regional production capabilities or in alternative supplier relationships to mitigate trade exposure. Health systems and distributors respond by diversifying their vendor base and by strengthening inventory management policies to accommodate potential disruptions. Clinicians and treatment centers may experience indirect effects through changes in product availability or delivery timelines, requiring increased coordination among manufacturers, distributors, and payers.

Finally, tariffs can influence strategic decision-making around product portfolios. Firms evaluating capital investments or portfolio expansions weigh trade-related risks alongside regulatory and clinical factors, with some opting to accelerate local capacity expansions or pursue licensing arrangements that reduce cross-border trade dependencies. Consequently, tariff measures serve as a significant exogenous variable that shapes operational choices, partnership strategies, and resilience planning across the sector.

A comprehensive segmentation-driven insight framework connecting source, end-user, distribution, product types, and clinical applications to reveal targeted strategic priorities

Segmentation analysis illuminates distinct commercial and clinical drivers across product classes and delivery models, offering a nuanced lens on where innovation and investment are concentrated. Based on Source, the market divides into plasma-derived and recombinant categories, with recombinant approaches further examined through the distinct clinical and manufacturing attributes of Factor IX and Factor VIII; these differences influence development timelines, regulatory pathways, and clinician adoption patterns. Based on End User, the evaluation distinguishes Hemophilia Treatment Centers, Home Care settings, and Hospitals, each presenting unique requirements for cold chain management, patient education, and adherence programs that shape distribution and support services.

Based on Distribution Channel, distribution pathways encompass Hospital Pharmacy, Online Pharmacies, Retail Pharmacy, and Specialist Clinics, creating diverse access points that affect point-of-care readiness and patient experience. Based on Product Type, product segmentation recognizes Albumin, Coagulation Factor, and Immunoglobulin, and further dissects the Coagulation Factor category into Factor IX, Factor VIII, and Fibrin Sealant while the Immunoglobulin group is evaluated across Hyperimmune, Intravenous, and Subcutaneous formulations; these product-level distinctions determine clinical use cases, preparation complexity, and storage considerations. Based on Application, therapeutic uses span Hemophilia Treatment, Neurological Disorders, and Primary Immunodeficiency, each driving specific clinical trial designs, outcome measures, and post-market surveillance needs. Synthesizing these segment-level insights enables stakeholders to align R&D focus, commercial strategy, and supply chain investments with the clinical and operational realities that govern uptake.

A multidimensional regional analysis revealing how Americas, Europe Middle East & Africa, and Asia-Pacific each shape regulatory strategy, manufacturing footprints, and patient access dynamics

Regional dynamics play a pivotal role in shaping production strategies, regulatory engagement, and patient access pathways across the industry. In the Americas, established manufacturing clusters and dense healthcare networks support widespread adoption of both plasma-derived and recombinant therapies, while policy and reimbursement environments continue to evolve around cost-effectiveness and equitable access. This region's research infrastructure and clinical trial capacity also make it a focal point for novel therapeutic evaluations and post-authorization safety monitoring.

In Europe, Middle East & Africa, regulatory harmonization efforts and diverse health system maturities produce a range of market entry considerations, from alignment with centralized approval frameworks to locally tailored access programs. Capacity constraints in certain markets within this region emphasize the importance of regional supply hubs, donor recruitment initiatives, and targeted patient support mechanisms. Meanwhile, Asia-Pacific presents a mix of rapidly growing demand, expanding local manufacturing capabilities, and variable regulatory pathways that collectively encourage strategic partnerships and licensing models to accelerate market entry. Across all regions, cross-border logistics, cold chain integrity, and local clinical practice patterns require manufacturers and distributors to adopt differentiated approaches to commercialization and operations to meet heterogeneous needs effectively.

An executive perspective on how incumbent producers, recombinant innovators, and contract manufacturers are reshaping competitive advantage through partnerships, modernization, and service differentiation

Competitive dynamics are shaped by a mix of legacy plasma fractionators, innovators in recombinant protein engineering, and specialized contract manufacturers that provide scale and technical expertise. Key players emphasize portfolio diversification, integrating plasma-derived offerings with recombinant therapeutics to balance supply risk and meet diverse clinical needs. Strategic priorities include investments in manufacturing modernization, expansion of pathogen-reduction technologies, and programs that strengthen donor recruitment and retention for plasma sourcing.

Collaborative models are increasingly common, with licensing deals, co-development partnerships, and contracted manufacturing agreements enabling faster time-to-market for novel formulations while mitigating capital intensity. Companies are also focusing on differentiated service models to support clinicians and patients, including enhanced patient education, adherence tools, and integrated home-care support for therapies suitable for at-home administration. Mergers and acquisitions activity continues to recalibrate competitive positioning as firms seek scale, geographic reach, and complementary technical capabilities to compete effectively in a landscape where product quality, supply resilience, and clinical support services are decisive factors.

Actionable recommendations focused on strengthening supply resilience, accelerating digital traceability, and aligning commercialization approaches with care settings and payer expectations

Leaders in the sector should prioritize integrated strategies that strengthen supply resilience while supporting clinical adoption and payer alignment. Investing in regional manufacturing and in redundant sourcing reduces vulnerability to trade disruptions and tariff-driven cost pressures, and concurrently supports faster response to local demand fluctuations. In parallel, organizations should accelerate adoption of digital quality systems and supply-chain traceability tools that enhance product safety oversight and regulatory compliance, thereby increasing confidence among clinicians and payers.

Commercially, firms will benefit from developing tailored access programs that address the needs of Hemophilia Treatment Centers, home-based care models, and hospital settings, ensuring distribution strategies align with each channel's operational needs. Strategic collaborations with clinical centers and patient advocacy groups can amplify real-world evidence collection and support reimbursement discussions. Finally, corporate decision-makers should embed scenario planning for policy and trade changes into capital investment assessments and partnership negotiations, ensuring that product portfolios and manufacturing footprints remain adaptable to shifting regulatory and economic conditions.

A transparent, mixed-methods research approach combining expert interviews, regulatory review, and scenario-based analysis to validate strategic insights and ensure methodological rigor

The research underpinning this analysis draws on a mixed-methods approach that synthesizes primary stakeholder engagement with rigorous secondary-source validation to create a robust and defensible evidence base. Qualitative inputs include structured interviews and consultation sessions with clinical experts, manufacturing leaders, regulatory affairs specialists, and distribution partners, designed to capture operational realities, adoption drivers, and perceived barriers across therapeutic categories. These perspectives are triangulated with technical literature, regulatory guidance documents, and publicly available clinical trial registries to ensure alignment with current scientific and policy contexts.

Analytical methods employ comparative scenario analysis to explore how changes in trade policy, manufacturing capacity, and distribution models affect strategic choices across stakeholders. A thematic synthesis approach is used to integrate insights from different segments and regions, highlighting cross-cutting trends and localized considerations without relying on proprietary or numerical market estimates. Quality assurance protocols include cross-validation of key findings by independent subject-matter reviewers and documented audit trails for source materials and interview protocols, ensuring transparency and reproducibility of the conclusions presented.

A conclusive synthesis emphasizing coordinated strategic responses that align scientific innovation, operational resilience, and tailored commercialization to improve patient access

In conclusion, the blood plasma derivatives and recombinant therapeutics landscape is marked by simultaneous opportunities and challenges that demand coordinated strategic responses. Scientific progress in recombinant engineering and improvements in plasma fractionation technology are expanding therapeutic options, while regulatory and payer expectations are heightening the emphasis on safety, traceability, and demonstrable real-world outcomes. Supply chain fragilities and geopolitical trade variables further complicate operational planning, underscoring the importance of diversified sourcing and regional capacity investments.

Stakeholders that proactively align R&D priorities, manufacturing strategies, and commercialization models with the differentiated needs of treatment centers, home-care programs, and hospital systems will be best positioned to deliver value to patients and health systems. By integrating robust risk-management practices, embracing digital quality tools, and cultivating collaborative partnerships, organizations can enhance resilience and accelerate the adoption of therapies that address pressing clinical needs. The sector's trajectory will be shaped by those who combine scientific excellence with operational foresight and pragmatic engagement with clinical and policy stakeholders, thereby translating innovation into sustainable patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Plasma Derivatives Market, by Product Type

  • 8.1. Albumin
  • 8.2. Coagulation Factor
    • 8.2.1. Factor IX
    • 8.2.2. Factor VIII
    • 8.2.3. Fibrin Sealant
  • 8.3. Immunoglobulin
    • 8.3.1. Hyperimmune
    • 8.3.2. Intravenous
    • 8.3.3. Subcutaneous

9. Blood Plasma Derivatives Market, by Source

  • 9.1. Plasma Derived
  • 9.2. Recombinant
    • 9.2.1. Factor IX
    • 9.2.2. Factor VIII

10. Blood Plasma Derivatives Market, by Distribution Channel

  • 10.1. Online
  • 10.2. Offline

11. Blood Plasma Derivatives Market, by Application

  • 11.1. Hemophilia Treatment
  • 11.2. Neurological Disorders
  • 11.3. Primary Immunodeficiency

12. Blood Plasma Derivatives Market, by End User

  • 12.1. Hemophilia Treatment Centers
  • 12.2. Home Care
  • 12.3. Hospitals

13. Blood Plasma Derivatives Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Blood Plasma Derivatives Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Blood Plasma Derivatives Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Blood Plasma Derivatives Market

17. China Blood Plasma Derivatives Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Bharat Serums and Vaccines Limited
  • 18.6. Bio Products Laboratory Limited (BPL)
  • 18.7. Biotest AG
  • 18.8. China Biologic Products Holdings, Inc.
  • 18.9. CSL Behring GmbH
  • 18.10. Emergent BioSolutions Inc.
  • 18.11. Grifols, S.A.
  • 18.12. Hualan Biological Engineering Inc.
  • 18.13. Intas Pharmaceuticals Ltd.
  • 18.14. Kamada Ltd.
  • 18.15. Kedrion S.p.A.
  • 18.16. LFB S.A.
  • 18.17. Octapharma AG
  • 18.18. Reliance Life Sciences Pvt. Ltd.
  • 18.19. Sanquin Plasma Products B.V.
  • 18.20. Shanghai RAAS Blood Products Co., Ltd.
  • 18.21. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
  • 18.22. SK Plasma Co., Ltd.
  • 18.23. Takeda Pharmaceutical Company Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ALBUMIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRIN SEALANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRIN SEALANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FIBRIN SEALANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HYPERIMMUNE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HYPERIMMUNE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HYPERIMMUNE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PLASMA DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PLASMA DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PLASMA DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR IX, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY FACTOR VIII, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRIMARY IMMUNODEFICIENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HEMOPHILIA TREATMENT CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 89. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. NORTH AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 98. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. LATIN AMERICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 122. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 123. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 152. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 153. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GCC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. GCC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. GCC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 159. GCC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 160. GCC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 161. GCC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 162. GCC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. GCC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. GCC BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPEAN UNION BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPEAN UNION BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPEAN UNION BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 179. BRICS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 180. BRICS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. BRICS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. BRICS BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. G7 BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. G7 BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. G7 BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 186. G7 BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 187. G7 BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 188. G7 BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 189. G7 BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 190. G7 BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. G7 BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. NATO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. NATO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. NATO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 195. NATO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 196. NATO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 197. NATO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 198. NATO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 199. NATO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. NATO BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 207. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 208. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY COAGULATION FACTOR, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY IMMUNOGLOBULIN, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 216. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 217. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 218. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 219. CHINA BLOOD PLASMA DERIVATIVES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)